Drugs / rNV-2v
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05508178 | Aug 2020 → Oct 2021 | norovirus infectious disease | Icon Genetics GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rNV-2v | “This clinical study will evaluate the vaccine candidate rNV-2v, which is under development to prevent disease triggered by noroviruses.” NCT05508178 ↗ |
| Modality | Vaccine | “The vaccine being tested in this study is rNV-2v; norovirus GI.4/GII.4 bivalent, virus-like particle (VLP) vaccine without adjuvant.” NCT05508178 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT05508178 ↗ |